Lantern Pharma Inc. (LTRN) income statement
LTRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 17, 2026Score 5/30
$0.33−0.04 (-9.78%)
Close on Nov 18, 2026Market cap $4.21MP/E –Yield –
Lantern Pharma Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -123.5%
Financial strength
- Current ratio
- 1.49
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 134.7%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.99
- Dividend yield
- –
See a number that looks wrong?